---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-176877"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:32:10.454657+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Minerva Neurosciences raises $20M in PIPE at $10/share for roluperidone launch

## Summary
- Gross proceeds ~$20M from 1,425,000 shares at $10/share and 575,575 pre-funded warrants at $9.99.
- Investors include Boehringer Ingelheim and Federated Hermes Kaufmann Funds; Boehringer gets board observer rights.
- Net proceeds to support U.S. regulatory approval, commercialization, and launch of roluperidone for negative schizophrenia symptoms.
- Closing expected on or about June 30, 2023, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001193125-23-176877
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312523176877/0001193125-23-176877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312523176877/d527050d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-176877
- JSON: https://secwatch.observer/filing/0001193125-23-176877.json
- Plain text: https://secwatch.observer/filing/0001193125-23-176877.txt

## Key facts
- Material Agreements
  Minerva Neurosciences, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors valued at approximately $20.0 million (effective 2023-06-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: approximately $20.0 million
  - Effective: 2023-06-27
  source text: On June 27, 2023, Minerva Neurosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 1,425,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $10.00 per Share, and (ii) in lieu of additional shares of Common Stock, pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 575,575 shares of Common Stock at a purchase price of $9.99 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1598646/000119312523176877/0001193125-23-176877-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.